We write as members of the international medical community to call upon the Israeli Medical Association (IMA) to uphold its commitment to ethical principles by supporting independent international ...

At Martha’s Vineyard, Touch Talks Wellness and BlackDoctor.org joined forces to host an urgent and deeply personal conversation on cancer disparities in the Black community. Powered by partnerships ...

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...

The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.

The company is testing its lead asset, a CAR T/NK-cell therapy, in a Phase I trial in patients with B-cell malignancies.

Defence Secretary Pete Hegseth has endorsed a Christian pastor who wrote that “unsubmissive” women are a “truly destructive ...

Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Gilead Sciences, in collaboration ...

Biotech investors tend to focus on small-cap companies in search of the next big breakthrough. Still, one established player ...

This is the Marion Star's high school football warehouse for the season, with links to all our content for the 2025 season.

Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.

These were among the concerns of a recent regulatory inspection of a key, but historically troubled, manufacturing plant that ...

Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy ...